Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ: IOVA )

3.200 +0.010 (+0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,994
Open 3.200
Bid (Size) 3.200 (4)
Ask (Size) 3.240 (3)
Prev. Close 3.190
Today's Range 3.190 - 3.200
52wk Range 2.700 - 14.23
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
Via The Motley Fool

Performance

YTD
-58.92%
-58.92%
1 Month
-11.85%
-11.85%
3 Month
-46.58%
-46.58%
6 Month
-67.41%
-67.41%
1 Year
-73.02%
-73.02%

More News

Read More
This Biotech Stock Could Be the Best Investment of the Decade
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Is Iovance Biotherapeutics a Millionaire-Maker?
Via The Motley Fool
Exposures Product Safety
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Via The Motley Fool
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month
Via Benzinga
What's Wrong With Iovance Biotherapeutics Stock?
Via The Motley Fool
Where Will Iovance Biotherapeutics Be in 5 Years?
Via The Motley Fool
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Via The Motley Fool
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Via The Motley Fool
These stocks are moving in today's after hours session
Via Chartmill
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
My 3 Favorite Stocks to Buy Right Now
Via The Motley Fool
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Shares Fell Today: What's Going On?
Via Benzinga
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.